PGV-1 is a Potent Antimitotic Agent

Carcinogenesis may resulted from the malfunctioning of programmed cell death. Most of the anticancer drugs in current use induce apoptosis in susceptible cells. The fact that disparate agent interacting with different targets seem to induce cell death through some common mechanisms suggest that anticancer activity is determined by the ability of inhibiting cell growth. Pentagamavunon-1 (PGV-1) is one of the curcumin analogues which showed to have potency in inhibiting proliferation of T47D human breast carcinoma cells. The effects on T47D cells growth is associated with cell cycle arrest in G2/M phase at the concentration of 2.5 ?M, followed by hyperploidy. The data on polymerization assay, indicated that PGV-1 interact with tubulin in different manner from taxol. PGV-1 inhibit tubulin polymerization on cell culture while taxol stabilized tubulin polymerization. Immunostainning data on PGV-1 treated cells showed slightly tubulin condensation, while taxol treated cells showed tubulin condensation distinctly at 12 minutes after releasing from depolymerizing agent. In conclusion, PGV-1 represent a new microtubule inhibitor and has the potential to be developed for antimitotic drug Key words: Pentagamavunon-1, T47D, tubulin